A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects with Gastroparesis
- Registry ID
- EUCTR2010-023186-21
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- GlaxoSmithKline Research and Development Ltd
- Start date
- 2011-01-11
- Completion date
- 2013-02-26
- Last update
- 2026-08-16
Conditions
Summary
To investigate the pharmacodynamic effect of 28 days of repeated doses of GSK962040 on gastric emptying of an isotope-labelled test meal, as measured by the 13C-oral breath test (OBT) in DM subjects with gastroparesis
Locations
- , , Belgium
- , , UK
- , , Sweden
View on source registry